Skye Bioscience, Inc.

SKYE · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Assets
Cash & Equivalents$68,416$1,256$1,245$8,983
Short-Term Investments$0$0$0$0
Receivables$5$158$74$0
Inventory$0$0$0$0
Other Curr. Assets$2,406$10,236$7,625$629
Total Curr. Assets$70,827$11,651$8,944$9,612
Property Plant & Equip (Net)$1,883$281$159$235
Goodwill$0$0$0$0
Intangibles$0$0$0$0
Long-Term Investments$0$0$0$0
Tax Assets$0$0$0$0
Other NC Assets$54$8$8$8
Total NC Assets$1,937$290$167$243
Other Assets$0$0$0$0
Total Assets$72,764$11,940$9,111$9,855
Liabilities
Payables$569$957$1,795$900
Short-Term Debt$182$4,444$1,983$2,057
Tax Payable$0$0$0$0
Deferred Revenue$0$0$0$0
Other Curr. Liab.$3,587$8,500$8,342$955
Total Curr. Liab.$4,339$13,901$12,119$3,912
LT Debt$273$171$0$79
Deferred Rev, NC$0$0$0$0
Deferred Tax Liab, NC$0$0$0$0
Other NC Liab.$0$0$0$0
Total NC Liab.$273$171$0$79
Other Liabilities$0$0$0$0
Cap. Leases$456$243$79$161
Total Liabilities$4,612$14,072$12,119$3,991
Equity
Pref Stock$0$0$0$0
Common Stock$31$12$4$476
Retained Earnings-$130,950-$104,383-$66,738-$47,256
AOCI$0$0$0$0
Other Equity$199,070$102,238$63,726$52,644
Total Equity$68,152-$2,132-$3,008$5,864
Supplemental Information
Minority Interest$0$0$0$0
Total Liab. & Tot. Equity$72,764$11,940$9,111$9,855
Net Debt-$67,960$3,359$738-$6,847